Long-Term Health: Monitoring Your Eyes, Heart, and Brain
At a Glance
MMA-HCU can affect the eyes, kidneys, heart, lungs, and brain over time, even when MMA and homocysteine blood levels are controlled. Regular, individualized monitoring helps detect retinal, kidney, heart, neurological, and psychiatric complications early.
While the daily management of Methylmalonic Acidemia with Homocystinuria (MMA-HCU) focuses on blood levels, the condition can affect multiple organ systems over time. Because the cblC defect impacts how every cell in the body functions, it requires long-term monitoring of the eyes, kidneys, heart, and brain [1][2]. Importantly, a normal current homocysteine or MMA result does not guarantee the absence of complications, reinforcing the need for ongoing clinical surveillance.
Protecting Your Vision
One of the most unique and challenging aspects of the cblC defect is its impact on the eyes, specifically the retina (the light-sensitive layer at the back of the eye).
In the early-onset form of the disease, a condition called maculopathy or retinal degeneration can begin very early, sometimes within the first few months of life [3][4]. This often shows up as “bull’s-eye” thinning in the center of the retina. Crucially, this eye damage can sometimes progress even when blood levels of MMA and homocysteine are well-controlled [3][5]. Regular exams with an ophthalmologist are essential and may include specialized tests depending on age, symptoms, and cooperation:
- Optical Coherence Tomography (OCT): A non-invasive imaging test that looks at the thickness of retinal layers [6].
- Electroretinography (ERG): A test that measures the electrical response of the eye’s light-sensitive cells [7].
While early therapy may slow progression, some retinal injury may be irreversible.
Kidney Health
The kidneys are also at risk, primarily from a condition called Thrombotic Microangiopathy (TMA). This occurs when tiny blood clots form in the small blood vessels of the kidney, leading to inflammation and potential kidney failure [1].
If kidney function declines, a patient might experience high blood pressure, swelling, or even require dialysis [1][8]. Evaluating for TMA requires a broad clinician-directed approach checking a CBC, platelets, a blood smear, bilirubin, LDH, creatinine, blood pressure, and urine protein. The good news is that rapid, high-dose treatment with hydroxocobalamin (B12) can often improve this damage. In some reported cases, patients were able to stop dialysis once their metabolic levels stabilized, though some kidney injury may be permanent [1].
Heart and Lung Considerations
A serious but often treatable complication is Pulmonary Hypertension (PH), which is high blood pressure in the arteries of the lungs. This forces the right side of the heart to work harder, which can lead to heart failure if left untreated [9][10].
Signs to watch for include sudden shortness of breath, turning blue around the lips (cyanosis), or extreme fatigue during play or exercise [10]. While PH can be life-threatening, research shows that it may improve significantly once proper metabolic treatment and targeted heart medications are started [11]. BNP (a marker of cardiac strain) and echocardiography are risk- and symptom-dependent surveillance tools, rather than automatically required screening tests for every patient at all times.
Neurological and Psychiatric Impact
The impact on the brain often depends on when the condition first appeared:
- Early-Onset (Infants): The focus is often on developmental milestones. Challenges can include hypotonia (low muscle tone), seizures, or delays in walking and talking [12][13]. Early and consistent treatment is the best way to support healthy brain development [14].
- Late-Onset (Teens and Adults): The impact is often more subtle and can be mistaken for other conditions. Common issues include neuropathy (numbness or weakness in the legs), “brain fog,” or sudden psychiatric changes like severe anxiety, mood swings, or even psychosis (losing touch with reality) [15][2][16].
The encouraging reality is that many of these neurological and psychiatric symptoms may improve substantially once treatment begins [17][18]. However, because some injury may be irreversible and require separate organ or psychiatric support, regular check-ins with your metabolic team are the best way to catch and treat issues early.
Common questions in this guide
Can MMA-HCU cause organ problems even when blood tests are normal?
Which eye tests are used to monitor MMA-HCU?
How is kidney injury from MMA-HCU evaluated?
What symptoms can suggest pulmonary hypertension in MMA-HCU?
What brain or mental health changes can MMA-HCU cause?
Get notified when new evidence is published on Methylmalonic acidemia with homocystinuria.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.
Beck BB, van Spronsen F, Diepstra A, et al.
Pediatric nephrology (Berlin, Germany) 2017; (32(5)):733-741 doi:10.1007/s00467-016-3399-0.
PMID: 27289364 - 2
Late-onset cblC deficiency around puberty: a retrospective study of the clinical characteristics, diagnosis, and treatment.
Chen Z, Dong H, Liu Y, et al.
Orphanet journal of rare diseases 2022; (17(1)):330 doi:10.1186/s13023-022-02471-x.
PMID: 36056359 - 3
Retinal Changes in Early-Onset cblC Methylmalonic Acidemia Identified Through Expanded Newborn Screening: Highlights from a Case Study and Literature Review.
Michieletto P, Baldo F, Madonia M, et al.
Genes 2025; (16(6)) doi:10.3390/genes16060635.
PMID: 40565527 - 4
Ocular disease in the cobalamin C defect: a review of the literature and a suggested framework for clinical surveillance.
Weisfeld-Adams JD, McCourt EA, Diaz GA, Oliver SC
Molecular genetics and metabolism 2015; (114(4)):537-46.
PMID: 25742969 - 5
Ophthalmic Manifestations and Long-Term Visual Outcomes in Patients with Cobalamin C Deficiency.
Brooks BP, Thompson AH, Sloan JL, et al.
Ophthalmology 2016; (123(3)):571-82.
PMID: 26825575 - 6
Optical coherence tomography morphology and evolution in cblC disease-related maculopathy in a case series of very young patients.
Bacci GM, Donati MA, Pasquini E, et al.
Acta ophthalmologica 2017; (95(8)):e776-e782 doi:10.1111/aos.13441.
PMID: 28481040 - 7
Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.
Bonafede L, Ficicioglu CH, Serrano L, et al.
Investigative ophthalmology & visual science 2015; (56(13)):7875-87 doi:10.1167/iovs.15-17857.
PMID: 26658511 - 8
Cobalamin c deficiency associated with antifactor h antibody-associated hemolytic uremic syndrome in a young adult.
Philipponnet C, Desenclos J, Brailova M, et al.
BMC nephrology 2020; (21(1)):96 doi:10.1186/s12882-020-01748-2.
PMID: 32164588 - 9
Long-term outcome of CblC deficiency complicated with pulmonary hypertension.
Ding S, Deng Y, Hao L, et al.
Orphanet journal of rare diseases 2025; (20(1)):276 doi:10.1186/s13023-025-03839-5.
PMID: 40468431 - 10
Pulmonary hypertension in late-onset Methylmalonic Aciduria and Homocystinemia: a case report.
Wen LY, Guo YK, Shi XQ
BMC pediatrics 2020; (20(1)):243 doi:10.1186/s12887-020-02130-9.
PMID: 32443968 - 11
Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy.
He R, Liu J, Tang X, et al.
Pediatric research 2026; (100(2)):776-781 doi:10.1038/s41390-025-04720-8.
PMID: 41454146 - 12
The Follow-Up of Chinese Patients in cblC Type Methylmalonic Acidemia Identified Through Expanded Newborn Screening.
Ling S, Wu S, Shuai R, et al.
Frontiers in genetics 2022; (13()):805599 doi:10.3389/fgene.2022.805599.
PMID: 35242167 - 13
Early neurodevelopmental characterization in children with cobalamin C/defect.
Ricci D, Martinelli D, Ferrantini G, et al.
Journal of inherited metabolic disease 2020; (43(2)):367-374 doi:10.1002/jimd.12171.
PMID: 31503356 - 14
Outcomes of patients with cobalamin C deficiency: A single center experience.
Bourque DK, Mellin-Sanchez LE, Bullivant G, et al.
JIMD reports 2021; (57(1)):102-114 doi:10.1002/jmd2.12179.
PMID: 33473346 - 15
Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review.
Arhip L, Brox-Torrecilla N, Romero I, et al.
Orphanet journal of rare diseases 2024; (19(1)):20 doi:10.1186/s13023-024-03021-3.
PMID: 38245797 - 16
Distinct clinical, neuroimaging and genetic profiles of late-onset cobalamin C defects (cb1C): a report of 16 Chinese cases.
Wang X, Yang Y, Li X, et al.
Orphanet journal of rare diseases 2019; (14(1)):109 doi:10.1186/s13023-019-1058-9.
PMID: 31092259 - 17
High-dose hydroxocobalamin achieves biochemical correction and improvement of neuropsychiatric deficits in adults with late onset cobalamin C deficiency.
Higashimoto T, Kim AY, Ogawa JT, et al.
JIMD reports 2020; (51(1)):17-24 doi:10.1002/jmd2.12087.
PMID: 32071835 - 18
Late-onset cobalamin C defect with a rare MMACHC c.457 C > T variant: a case report and literature review.
Huang Q, Liao Z, Li H, et al.
BMC pediatrics 2026; (26(1)).
PMID: 42897485
This page explains long-term organ monitoring for MMA-HCU for educational purposes only and does not replace medical advice. Ask your metabolic team how to tailor eye, kidney, heart, and neurological follow-up to your or your child’s needs.